Navigation Links
Conatus Pharmaceuticals Will Display HCV Clinical Trial Data at the International Liver Congress™ (EASL) in March
Date:3/11/2011

SAN DIEGO, March 11, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced the acceptance of two poster presentations of Phase 2 clinical trial data of CTS-1027 for the treatment of hepatitis C virus-infected patients at the 46th annual meeting of the European Association for the Study of the Liver (EASL) to be held in Berlin, Germany, on March 30 to April 3, 2011.

Specifically, abstract 562 entitled: 24-WEEK TREATMENT WITH CTS-1027 IN COMBINATION WITH RIBAVIRIN REDUCES HCV-RNA IN TREATMENT NAIVE GENOTYPE-1 PATIENTS will be presented.

In addition, abstract 549 entitled: UNIQUE PATTERN OF VIROLOGIC RESPONSE IN PATIENTS WITH GENOTYPE-1 HCV: A PHASE II STUDY OF CTS-1027 IN COMBINATION WITH PEGINTEFERON/RIBAVIRIN (SOC) IN NULL RESPONDERS will also be presented.

"This will be the first public disclosure of these exciting clinical results and represents a significant step forward to raise awareness of CTS-1027 for the treatment of HCV," said Alfred P. Spada, Ph.D., Senior Vice President, Research and Development at Conatus.

"CTS-1027 is a first-in-class oral, small molecule inhibitor of host matrix metalloprotease (MMP) activity.  There are no other drugs under development for HCV that operate by the same mechanism of action.  Most other approaches to treat HCV infection are direct-acting anti-viral drugs whose activity is directed against virus proteins or enzymes with the objective of reducing the production of virus in infected cells.  CTS-1027 by comparison is distinctly different in that its activity is hypothesized to facilitate the immune clearance of virus-infected cells and decrease the frequency of new infections, both of which are of key importance in curing HCV infections," said Steven J. Mento, Ph.D, President and CEO of Conatus.

Conatus Pharmaceuticals Inc. is a privately-held biopharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease and oncolo
'/>"/>

SOURCE Conatus Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
2. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
3. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
4. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
5. Conatus Pharmaceuticals Acquires Pfizers Idun Subsidiary
6. Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing
7. Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial of CTS-1027 for the Treatment of Hepatitis C Virus (HCV)
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014  According to data released today by ... average monthly Medicare Part D premium is expected to ... was originally projected, the Pharmaceutical Care Management Association (PCMA) ... to be a bright spot in American health care. ... region and using cutting edge, cost-saving tools like pharmacy ...
(Date:7/31/2014)... -- IRIDEX Corporation (Nasdaq: IRIX ) today reported ... June 28, 2014.  , Revenues were $10.6 million ... million in the 2013 second quarter and up sequentially from ... the first six months of 2014 were $20.9 million, up ... last year. , Gross margin for the quarter was ...
(Date:7/31/2014)... Xencor Inc. (NASDAQ: XNCR ), a ... the treatment of autoimmune diseases, asthma and allergic ... the second quarter ended June 30, 2014 and provided ... "In the second quarter, we presented preclinical data ... (ATS) demonstrating three novel mechanisms of action of ...
Breaking Medicine Technology:IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6Xencor Reports Second Quarter 2014 Financial Results 7Xencor Reports Second Quarter 2014 Financial Results 8
... on Monday, December 10, 2007, NEW HAVEN, Conn., ... today announced that preliminary data,from its pivotal Phase II ... acute myelogenous leukemia (AML) would be presented,in a poster ... in,Atlanta, Georgia on Saturday, December 8, 2007., The ...
... 5 Replidyne, Inc.,(Nasdaq: RDYN ) announced today ... participate on the New and Powerful Anti-infectives,panel at the ... take place at 11:00 am ET on Thursday, December ... City., A live audio webcast of the panel ...
Cached Medicine Technology:Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting 2Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting 3
(Date:8/1/2014)... iFitDress.com, one of the most famous dress suppliers in the ... dresses online. At the moment, all the brand new ... According to the company’s senior spokesman, the special offer will ... stock is limited. Those who are thinking of buying cheap ... possible. All its products are delicately made by top designers. ...
(Date:8/1/2014)... The Judicial Panel on Multidistrict Litigation (JPML) issued ... strokes, heart attacks, and other injuries in men who ... as the transferee judge and ordered what could be ... , As one of his first organizing acts, Judge ... who will move the litigation forward on behalf of ...
(Date:8/1/2014)... University School of Medicine in St. Louis helps explain ... frequently are more harmful than similar tumors in females. ... are diagnosed twice as often in males, who suffer ... as long. , The researchers found that retinoblastoma protein ... significantly less active in male brain cells than in ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Parker Waichman ... rights of victims injured by defective medical devices and ... be recalling its Ethicon surgical power morcellator devices used ... sited concerns involving the spread of cancer associated with ... dated July 31, 2014. , Johnson & Johnson ...
(Date:8/1/2014)... York (PRWEB) August 01, 2014 ... the wake of the 2012 Rejuvenate and ABG ... forward in New Jersey’s Bergen County Superior Court, ... in the proceeding, the Court has issued ... governing any and all hard copy and electronic ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Top Bridesmaid Dresses For The Global Customers 2Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2Health News:Study reveals one reason brain tumors are more common in men 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 3Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 4Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3
... expanding care and care management,company, BRENTWOOD, Tenn., ... care management for the frail elderly,announced today that ... has been appointed to its board of directors., ... management company focused on,improving the quality of life ...
... The Smart Circle,International, LLC, the nation,s leader in ... Health Associates, Inc.,has put together the first-ever National ... and wellness-based physicians that,see preventative and maintenance care ... States., Thomas Edison once stated, "The doctor ...
... Available in Time for Spring Allergy ... ... Zagat Survey(R) guide, launched today, offers people with,seasonal and year-round allergies an ... and tips on how to manage their,allergy symptoms so they can enjoy ...
... Latest SmartSlide ... ... Board: WGBS), a leading developer of,state-of-the-art gene expression, genotyping, cell biology ... SmartSlide 200,Micro-Incubation System, the latest offering in its SmartSlide product,line. The ...
... Physicians and,Nurses Against Tobacco, Inc., (PANAT) an ... petitioning Pope Benedict,XVI to condemn the production, distribution, ... of State, to declare the Vatican the first ... political, spiritual, and moral leader,to set an example ...
... Cardiac Science,Corporation (Nasdaq: CSCX ), a ... and informatics products, announced that,Mexico,s Instituto de ... Estado (ISSSTE) ordered 282 electrocardiograph systems (ECGs) ... Science history. Instrumentation,Technologies de Mexico, Cardiac Science,s ...
Cached Medicine News:Health News:Stuart Altman, Ph.D. Joins INSPIRIS Board of Directors 2Health News:Stuart Altman, Ph.D. Joins INSPIRIS Board of Directors 3Health News:Smart Circle International, LLC Launches Its National Health and Wellness Network Complimentary 1/2-Hour Massage for Everyone 2Health News:20-City Zagat Survey(R) Guide Spotlights Outdoor Destinations and Offers Allergy Management Tips 2Health News:20-City Zagat Survey(R) Guide Spotlights Outdoor Destinations and Offers Allergy Management Tips 3Health News:WaferGen Launches SmartSlide 200 Micro-Incubation System for Stem Cell Research and Cell Biology Applications 2Health News:WaferGen Launches SmartSlide 200 Micro-Incubation System for Stem Cell Research and Cell Biology Applications 3Health News:WaferGen Launches SmartSlide 200 Micro-Incubation System for Stem Cell Research and Cell Biology Applications 4Health News:WaferGen Launches SmartSlide 200 Micro-Incubation System for Stem Cell Research and Cell Biology Applications 5Health News:WaferGen Launches SmartSlide 200 Micro-Incubation System for Stem Cell Research and Cell Biology Applications 6Health News:Physicians and Nurses Against Tobacco (PANAT) Petition Pope Benedict XVI to Condemn Tobacco Industry, and Tobacco Use, and Declare Vatican First Tobacco- Free Country 2Health News:Cardiac Science Delivers Largest Order of Electrocardiograph Systems in Company History 2Health News:Cardiac Science Delivers Largest Order of Electrocardiograph Systems in Company History 3Health News:Cardiac Science Delivers Largest Order of Electrocardiograph Systems in Company History 4
... ready-to-use solutions ideal for a wide range ... prepared with 18 megOhm water, filtered using ... sterile bottles., Reliable - Manufactured according ... lot-to-lot consistency. , High Quality - ...
12% Tryptone, 24% Yeast Extract, 4.0% Glycerol. Supplied with 1 liter of 10x phosphate buffer (0190-1L)....
1.2% Tryptone, 2.4% Yeast Extract, 0.4% Glycerol, with 100ml of 10x Phosphate buffer supplement (0190-01)....
10% Casein digest (NZ amine), 5.0% Sodium Chloride, 5.0% Yeast Extract....
Medicine Products: